These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 33036717)
41. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Mishra A; Singh M; Acker WW; Kamboj S; Sporn D; Stapleton D; Kaluski E J Cardiovasc Pharmacol; 2019 Aug; 74(2):82-90. PubMed ID: 31306367 [TBL] [Abstract][Full Text] [Related]
42. Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany. Zeymer U; Toelg R; Wienbergen H; Hobbach HP; Cuneo A; Bekeredjian R; Ritter O; Hailer B; Hertting K; Hennersdorf M; Scholtz W; Lanzer P; Mudra H; Schwefer M; Schwimmbeck PL; Liebetrau C; Thiele H; Claas C; Riemer T; Zahn R Herz; 2023 Mar; 48(2):134-140. PubMed ID: 35243515 [TBL] [Abstract][Full Text] [Related]
43. Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified. Andrade JG; Deyell MW; Wong GC; Macle L Can J Cardiol; 2018 Nov; 34(11):1426-1436. PubMed ID: 30404748 [TBL] [Abstract][Full Text] [Related]
44. Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Benetou DR; Varlamos C; Mpahara A; Alexopoulos D Am J Cardiovasc Drugs; 2021 Jan; 21(1):11-20. PubMed ID: 32170515 [TBL] [Abstract][Full Text] [Related]
45. Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Hoshi T; Sato A; Nogami A; Gosho M; Aonuma K; J Cardiol; 2017 Apr; 69(4):648-651. PubMed ID: 27443596 [TBL] [Abstract][Full Text] [Related]
46. Meta-analysis of Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Kuno T; Ueyama H; Takagi H; Ando T; Numasawa Y; Briasoulis A; Fox J; Bangalore S Am J Cardiol; 2020 Feb; 125(4):521-527. PubMed ID: 31839147 [TBL] [Abstract][Full Text] [Related]
47. Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention. Pareek M; Bhatt DL; Ten Berg JM; Kristensen SD; Grove EL Expert Opin Pharmacother; 2017 Jun; 18(9):875-883. PubMed ID: 28489475 [TBL] [Abstract][Full Text] [Related]
48. Antithrombotic therapy trends in non-valvular atrial fibrillation patients undergoing percutaneous coronary stent implantation: Results from a survey among fellows at the Japanese College of Cardiology. Fukamachi D; Hirayama A; Miyauchi K; Yasuda S; Ogawa H; Ito H; Daida H J Cardiol; 2018 Aug; 72(2):113-119. PubMed ID: 29599096 [TBL] [Abstract][Full Text] [Related]
49. Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation. Godino C; Pivato CA; Rubino C; Russi A; Cera M; Margonato A Am J Cardiol; 2020 Aug; 129():122-124. PubMed ID: 32540165 [No Abstract] [Full Text] [Related]
51. Triple antithrombotic therapy in patients with atrial fibrillation undergoing PCI: current evidence and practice. Clarke A; Ibrahim A; Kiernan TJ Expert Rev Cardiovasc Ther; 2018 Oct; 16(10):715-723. PubMed ID: 30213212 [TBL] [Abstract][Full Text] [Related]
52. [Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis]. Yuan C; Zhong L; Huang RC Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jun; 45(6):526-535. PubMed ID: 28648031 [No Abstract] [Full Text] [Related]
53. Does HAS-BLED risk score underestimate the risk of bleeding in patients with triple antithrombotic therapy? Stojanovic M; Deljanin-Ilic M; Ilic S; Ilic B; Petrovic D Pol Merkur Lekarski; 2020 Oct; 48(287):361-364. PubMed ID: 33130800 [TBL] [Abstract][Full Text] [Related]
54. Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. Costa F; Valgimigli M; Steg PG; Bhatt DL; Hohnloser SH; Ten Berg JM; Miede C; Nordaby M; Lip GYH; Oldgren J; Cannon CP Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):216-226. PubMed ID: 33258897 [TBL] [Abstract][Full Text] [Related]
55. Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: A focused review. Chang KW; Arbit B; Hsu JC Int J Cardiol; 2017 Sep; 243():263-269. PubMed ID: 28595745 [TBL] [Abstract][Full Text] [Related]
56. Antithrombotic regimens in patients with indication for long-term anticoagulation undergoing coronary interventions-systematic analysis, review of literature, and implications on management. Deshmukh A; Hilleman DE; Del Core M; Nair CK Am J Ther; 2013; 20(6):654-63. PubMed ID: 21519218 [TBL] [Abstract][Full Text] [Related]
57. [Oral anticoagulants in elderly patients with coronary artery disease and atrial fibrillation]. Gallet R; Teiger E Ann Cardiol Angeiol (Paris); 2018 Dec; 67(6):404-410. PubMed ID: 30342831 [TBL] [Abstract][Full Text] [Related]